论文部分内容阅读
目的探讨扶他林联合益赛普对强直性脊柱炎患者近期疗效及生存质量的影响。方法选取94例强直性脊柱炎(AS)患者为研究对象,随机分成A、B两组,每组47例。B组采用扶他林单一用药方案,A组则采用扶他林联合益赛普用药方案。记录两组患者治疗前后各项体征及实验室检查结果 ,对比其临床疗效。结果治疗后,A组腰背痛、外周肿胀及晨僵等各项体征状况改善情况均优于B组患者,组间对比差异具有统计学意义(P<0.05);B组红细胞沉降率与肿瘤坏死因子α水平均高于A组,C反应蛋白水平低于A组,组间对比差异具有统计学意义(P<0.05);A组总有效率为78.72%,明显高于B组的48.94%,组间对比差异具有统计学意义(P<0.05)。结论对AS患者给予扶他林联合益赛普给药方案进行治疗,可有效提高患者近期治疗效果,改善患者生存质量,有临床推广价值。
Objective To investigate the effect of fadarin combined with etanercept on short-term efficacy and quality of life in patients with ankylosing spondylitis. Methods Ninety-four patients with ankylosing spondylitis (AS) were selected and randomly divided into A and B groups, with 47 cases in each group. Group B was given a single doping program, while group A was used doping group combined with etanercept. The signs and laboratory findings of both groups before and after treatment were recorded and their clinical effects were compared. Results After treatment, the signs and symptoms of lower back pain, peripheral swelling and morning stiffness in group A were better than those in group B, the difference was statistically significant (P <0.05); the erythrocyte sedimentation rate in group B was significantly lower than that in tumor (P <0.05). The total effective rate of group A was 78.72%, which was significantly higher than that of group B (48.94%). The level of C-reactive protein in group A was lower than that of group A , The difference between the groups was statistically significant (P <0.05). Conclusions The treatment of patients with AS in combination with fufanglin and eprister can effectively improve the treatment effect and improve the quality of life of patients with clinical promotion value.